Executive Director
Passage Bio
Philadelphia, Pennsylvania
Yan G. Ni, Ph.D., is a recognized biopharmaceutical professional with 20 years’ experience in drug development, translational medicine, clinical biomarker studies, and regulated bioanalysis. Her industry experience spans small molecules, biologics, and gene therapeutic product development for cardiovascular metabolic diseases, neurodegenerative diseases, and immuno-oncology. Ni is the executive director of Biomarkers and Precision Medicine at Passage Bio, a gene therapy company, where she leads the strategic planning and execution of clinical biomarkers and bioanalytical studies. Prior to this role, she held key positions at Regeneron Pharmaceuticals, Bristol-Myers Squibb, and Merck Research Laboratories, contributing to precision medicine, bioanalytical sciences, and translational research. She earned her doctorate in neuroscience from the University of California, Irvine, has published over 35 research papers/book chapters in peer-reviewed journals, and holds multiple patents.
Beyond her industry contributions, Ni has been highly involved in several professional organizations, including in AAPS, the Sino-American Pharmaceutical Professionals Association (SAPA), and the China Bioanalysis Forum. She chaired both the AAPS Biomarkers and Precision Medicine Community (2016–2017) and the Gene and Cell Therapy Products Community (2024). Additionally, she had led fundraising and public relations efforts at SAPA.
Contact information: yni@passagebio.com
Disclosure information not submitted.
Shedding Study in AAV-Gene Therapy Trials: What We Have Learned?
Wednesday, November 12, 2025
9:00 AM - 9:30 AM CT